• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Effect of α-1-adrenolytic agent and 5-α-reductase inhibitor on renal function in an experimental model of hyperprolactinemia-induced benign prostatic hyperplasia.

作者信息

Dobrek Łukasz, Nalik-Iwaniak Klaudia, Arent Zbigniew

机构信息

Department of Clinical Pharmacology, Wroclaw Medical University, Poland.

Experimental and Innovative Medicine Centre, University Centre of Veterinary Medicine, University of Agriculture in Krakow, Poland.

出版信息

Pol Merkur Lekarski. 2020 Jun 17;48(285):188-194.

PMID:32564045
Abstract

UNLABELLED

The standard pharmacotherapy of benign prostatic hyperplasia (BPH) may also alleviate potential kidney dysfunction resulting from the development of obstructive uropathy in the course of BPH.

AIM

The aim of study was to evaluate the effect of treatment with α-1- adrenolytic agent (tamsulosin) and 5-α-reductase inhibitor (finasteride) on renal function in rats.

MATERIALS AND METHODS

Four groups of rats were studied: 1 - controls, 2 - rats with metoclopramide-induced hyperprolactinemia BPH model, 3 - rats with BPH treated with tamsulosin, 4 - rats with BPH treated with finasteride. BPH presence was verified by histopathological examination. The renal function was assessed by histopathological examination, and the laboratory assessment of the classic nitrogen parameters and new kidney function markers (cystatin C; CysC, kidney injury molecule-1; KIM-1).

RESULTS

In group 2, BPH development was confirmed by histopathological examination, without simultaneous significant kidney disturbances. Compared to the controls, BPH animals exhibited significant proteinuria, and increased concentration and daily urinary excretion of CysC and KIM- 1. Treatment with tamsulosin significantly improved the histopathological image of the prostate without affecting renal structure and led to reduced blood urea and proteinuria. Treatment with finasteride also significantly reduced the histopathological signs of BPH without changing the image of the kidneys, and reduced CysC concentration and daily CysC excretion with urine compared to group 2 individuals.

CONCLUSIONS

In the course of experimental hyperprolactinemiainduced BPH, kidney tubulopathy developed, which was indicated by KIM-1 and CysC disturbances in urine. The administration of finasteride reduced renal dysfunction to a higher degree, bringing the concentration and daily excretion of CysC back to normal.

摘要

相似文献

1
Effect of α-1-adrenolytic agent and 5-α-reductase inhibitor on renal function in an experimental model of hyperprolactinemia-induced benign prostatic hyperplasia.
Pol Merkur Lekarski. 2020 Jun 17;48(285):188-194.
2
Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data.中国接受非那雄胺与α受体阻滞剂联合治疗与单独接受α受体阻滞剂治疗良性前列腺增生(BPH)患者的特征比较:电子病历数据分析。
Adv Ther. 2018 Aug;35(8):1191-1198. doi: 10.1007/s12325-018-0748-3. Epub 2018 Jul 16.
3
Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.单药治疗与联合药物治疗良性前列腺增生症
Am J Geriatr Pharmacother. 2005 Jun;3(2):103-14. doi: 10.1016/s1543-5946(05)00031-0.
4
Chinese Skullcap (Scutellaria baicalensis Georgi) inhibits inflammation and proliferation on benign prostatic hyperplasia in rats.黄芩(Scutellaria baicalensis Georgi)抑制大鼠良性前列腺增生的炎症和增殖。
J Ethnopharmacol. 2019 May 10;235:481-488. doi: 10.1016/j.jep.2019.01.039. Epub 2019 Jan 29.
5
Uvaria rufa Blume attenuates benign prostatic hyperplasia via inhibiting 5α-reductase and enhancing antioxidant status.红野独活通过抑制5α-还原酶和增强抗氧化状态来减轻良性前列腺增生。
J Ethnopharmacol. 2016 Dec 24;194:483-494. doi: 10.1016/j.jep.2016.10.036. Epub 2016 Oct 11.
6
Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.良性前列腺增生相关下尿路症状药物治疗中的药物依从性和药物相关问题。
J Physiol Pharmacol. 2018 Aug;69(4). doi: 10.26402/jpp.2018.4.14. Epub 2018 Dec 9.
7
Evaluation of the clinical indications, adverse drug reactions, and finasteride use in patients with benign prostatic hyperplasia in Poland.波兰良性前列腺增生患者的临床指征、药物不良反应及非那雄胺使用情况评估。
Pharmacol Rep. 2014 Aug;66(4):565-9. doi: 10.1016/j.pharep.2014.02.022. Epub 2014 Apr 26.
8
[Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].非那雄胺或度他雄胺治疗良性前列腺增生期间的前列腺特异性抗原变化
Minerva Urol Nefrol. 2013 Sep;65(3):211-6.
9
Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model.杠柳通过调节 5α-还原酶和雄激素受体活性改善睾酮诱导的大鼠良性前列腺增生。
Nutrients. 2017 Sep 27;9(10):1070. doi: 10.3390/nu9101070.
10
Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.接受度他雄胺或非那雄胺治疗的男性良性前列腺增生患者的前列腺手术率及急性尿潴留发生率。
BMC Urol. 2016 Aug 31;16(1):53. doi: 10.1186/s12894-016-0170-6.